Form 4: Corcept Therapeutics Officer Sells Shares in Recent Transaction

A Corcept Therapeutics officer, Joseph Douglas Lyon, sold 1,411 shares of common stock at $56.72 per share on November 22, 2024.

Summary

• Joseph Douglas Lyon, Chief Accounting & Technology Officer at Corcept Therapeutics, sold 1,411 shares of common stock on November 22, 2024.
• The sale price was $56.72 per share.
• Following the transaction, Mr. Lyon still beneficially owns 8,494 shares, which includes unvested restricted stock awards.
• These unvested awards include 460 shares granted on December 1, 2023, 507 shares granted on March 1, 2024, and 1,232 shares granted on June 3, 2024.
• The restricted stock awards vest on the one-year anniversary of the grant date, contingent on certain requirements being met.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a stock sale by an officer. It is a neutral event and does not indicate positive or negative sentiment.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It provides transparency into the transactions of company officers.

Comparison to Industry Standards

• SEC Form 4 filings are standard practice for publicly traded companies in the United States.
• The reporting requirements are consistent across all companies and are designed to ensure transparency in insider trading.
• The sale of shares by an officer is a common occurrence and does not necessarily indicate a negative outlook for the company.

Stakeholder Impact

• The stock sale may have a minor impact on the share price, but it is unlikely to be significant.
• The transaction provides transparency to shareholders regarding insider activity.

Key Dates

Keywords

Corcept Therapeutics, CORT, insider trading, stock sale, Joseph Douglas Lyon, restricted stock, executive compensation, SEC Form 4